Artificial Intelligence-based
Praedigo tackles the high burden of diabetes and obesity comorbidities by using cutting-edge AI models trained on thousands of patients to support physicians in an early diagnosis.
Around one of three T2DM patients develops chronic kidney disease¹
Half of the diabetes patients are estimated to develop diabetic polyneuropathy²,
Around one of three T2DM patients develops cardiovascular diseases³
Our AI Models
Our models correctly identify 82% of CKD patients and 79% of DPN patients, while keeping the number of false diagnosis moderately low. In contrast, the current healthcare systems only diagnose up to 35%⁶ of stage 3 CKDs and 23%² of DPNs.
Further, we interpret our models to identify important patterns and events that will improve the diagnosis of diabetes comorbidities further.
Improve the quality of life of diabetes patients
Support physicians in their decision-making and reduce time and cost efforts
Early identification of patients and simplified patient recruitment for clinical trials
Reduce costs for the healthcare system by earlier diagnosis of comorbidities
If you are interested in Praedigo we would be happy to discuss potential collaborations. Reach out to us.
References